Jubilant and Endo Pharmaceuticals Announce Late Stage Discovery Milestone in Oncology Program

By Jubilant Biosys Ltd, PRNE
Sunday, June 19, 2011

BENGALURU, India, June 20, 2011 -


 

Jubilant Biosys Ltd., Bengaluru based subsidiary of
Jubilant Life Sciences Ltd., and Endo Pharmaceuticals (Nasdaq:
ENDP), of Chadds Ford, Pa, U.S.A., announced today that they have
achieved a late stage discovery milestone in their joint program
focused on cancer.  

This is the third milestone in the two-year-old,
multi-target, oncology focused partnership and enables the
collaboration to rapidly pursue a development candidate. Endo and
Jubilant had entered into a multiyear, multi-target oncology
focused partnership in 2009. As a part of the partnership, Jubilant
delivers preclinical development candidates and has an option to
participate in clinical development. Endo owns the development and
commercial rights to the successful outcomes.  However,
Jubilant derives research funding, development milestones and sales
royalties on successful commercialization.

Commenting on this development, Sri Mosur, CEO&
President, Global Drug Discovery & Development,
Jubilant
said: We are pleased that we
continue to enhance the portfolio outcomes for Endo
Pharmaceuticals. It is an important achievement in our
collaboration and demonstrates our
scientist
s commitment to Oncology
research to deliver differentiated therapies to cancer patients
worldwide. It will be our continued endeavor to support the
collaboration in accelerating the development phase towards
successful commercialization

Sandeep Gupta, Sr. Vice President, Discovery and Early
Development
, Endo Pharmaceuticals commented: “We
are pleased with the technical capabilities and productivity of the
Jubilant team. They have done an outstanding job of designing novel
molecules and to
demonstrate preclinical proof of
concept ahead of schedule. We look forward to nominating a
development candidate in the near
future.

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of
Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant
Biosys, provides integrated drug discovery and development
solutions to the global pharmaceutical industry. It is a pioneer in
collaborative discovery research and development   and is
engaged in multiple partnerships with global pharmaceutical
industry in therapeutic areas of Oncology, CNS and CVMED. href="www.jubilantbiosys.com">www.jubilantbiosys.com

Endo Pharmaceuticals is a US based, specialty healthcare
solutions company, focused on high-value branded products and
specialty generics. We aim to be the premier partner to healthcare
professionals and payment providers, delivering an innovative suite
of complementary diagnostics, drugs, devices and clinical data to
meet the needs of patients in areas such as pain, urology, oncology
and endocrinology. href="www.endo.com">www.endo.com

Contact For Business Queries
lang="IT">narendra_kumar@jubilantbiosys.com

+91-9611104886

 

.

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :